Phase 2 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to volunteer to take part in the study
• People aged 18 to 75 years old (including age 75), of any gender
• People who have been diagnosed with stomach cancer or cancer at the junction of the stomach and oesophagus, confirmed by laboratory testing of tissue or cell samples
• People whose cancer is at clinical stage II or III, meaning it has not spread to distant parts of the body (confirm specific staging details with trial site)
• People who have not yet received any systemic (whole-body) treatment for their cancer
• People whose cancer tests positive for a protein called HER2, at a level of IHC 3+ or IHC 2+ (prior test results may be accepted if confirmed by the trial doctor)
• People who have at least one measurable area of cancer that can be assessed on scans
• People whose expected survival is at least 6 months
• People who are generally well enough to carry out light activity and care for themselves (a medical fitness score of 0 or 1 on a standard scale)
• People whose major organs such as the heart, liver, and kidneys are functioning normally

Who may not be able to join:

• People with a history of another cancer, unless they had treatment that may have cured it with no signs of disease for at least 5 years, or unless it was a certain type of skin cancer, early-stage bladder cancer, or cervical carcinoma in situ that was successfully removed
• People with conditions that could affect how the body absorbs or processes the study drug, such as severe vomiting, long-term diarrhoea, bowel blockage, or absorption problems
• People who have had a bone marrow or solid organ transplant from another person in the past
• People who have received any other cancer treatment (including certain traditional Chinese medicines used for cancer) within the past 4 weeks, or whose side effects from previous treatment have not yet sufficiently resolved
• People with a current or past immune system deficiency condition, whether present from birth or developed later in life
• People with active or previously recorded autoimmune or inflammatory conditions (such as lupus, inflammatory bowel disease, autoimmune hepatitis, certain thyroid conditions, or asthma requiring ongoing treatment, among others) — though people with vitiligo or childhood asthma that has fully resolved without ongoing treatment may still be eligible (confirm with trial site)
• People who have used immune-suppressing medications in the 2 weeks before joining, or who are expected to need them during the study, with some exceptions such as low-dose steroids or inhaled/topical steroids (confirm with trial site)
• People who are allergic to the study drug
• People who have had a blood clot, stroke, or related event such as deep vein thrombosis or pulmonary embolism in the past 6 months
• People considered to be at high risk of serious bleeding
• People with significant heart or cardiovascular conditions
• People with other notable abnormalities in clinical or laboratory results that the trial doctors consider a safety concern
• People with a serious active or poorly controlled infection
• People who have not yet fully recovered from a recent surgery
• Women who are pregnant or breastfeeding, or any person of reproductive capacity who is unwilling or unable to use effective contraception during the trial
• People whom the trial doctors consider unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.